Search results
Moderna Just Gave Investors Another Reason to Buy the Stock | The Motley Fool
The Motley Fool· 5 days agoModerna (MRNA -3.58%) is best known for its work in the coronavirus vaccine market. Let's look...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 1 day agoEarlier in the year, one analyst called results from the cancer vaccine study "transformational."...
Moderna (NASDAQ:MRNA) Stock Price Down 3.9% After Insider Selling
ETF DAILY NEWS· 1 day agoModerna, Inc. (NASDAQ:MRNA – Get Free Report)’s share price fell 3.9% during trading on Tuesday following insider selling activity. 1,055,980 shares changed hands during mid-day ...
Moderna Stock (NASDAQ:MRNA): Is There Life Beyond Disease Outbreaks?
TipRanks via Yahoo Finance· 4 days agoModerna (NASDAQ:MRNA) stock has surged 40.8% since the turn of the year. Some of this momentum can...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 6 hours agoBiotech stocks hit a two-year high in February, but have trended sideways in the months since...
GAMMA Investing LLC Purchases 822 Shares of Moderna, Inc. (NASDAQ:MRNA)
ETF DAILY NEWS· 2 days agoGAMMA Investing LLC grew its position in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 37.8% in the first quarter, HoldingsChannel reports. The fund owned 2,994 shares ...
Moderna stock is lone omen of bird flu pandemic
Reuters· 4 days agoThe recent rise of Moderna’s stock tells a grim tale. The $56 billion company which pioneered a Covid vaccine has seen its market value rise 40% since...
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Investor's Business Daily· 6 hours agoNovavax shares aren't forming a chart pattern. The Sanofi deal is a positive for Novavax and could...
COVID summer wave grows, especially in West, with new variant LB.1 on the rise
CBS News· 1 hour agoA summertime wave of COVID-19 infections is arriving earlier than last year across a growing share...
The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly
Zacks via Yahoo Finance· 9 hours agoIts revenues have jumped from $28.3 billion in 2021 to $34.1 billion in 2023. Conclusion While other...